- 询价
- Leading Biology
- LBP71722
- 美国
- 2026年03月13日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
存储在2 - 8°C 2周，长期存储-20°C,防止冻融循环。
- 英文名：
Anti-Human BID (C-Terminal) Antibody
- 供应商：
安诺伦（北京）生物科技有限公司
靶点/蛋白：ABD10897 detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, which is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the death stimuli. BID has been shown to promote cell cycle progression into S phase, whilst BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint. Deletion of BID inhibits carcinogenesis in the liver, and promotes tumorigenesis in the myeloid cells.
来源：Goat
参考文献：1. Yin, X.M. (2006) Bid, a BH3-only multi-functional molecule, is at the cross road of life and death.
Gene. 369: 7-19.
特异性：Human
别名：BH3-interacting domain death agonist, p22 BID, BID, BH3-interacting domain death agonist p15, p15 BID, BH3-interacting domain death agonist p13, p13 BID, BH3-interacting domain death agonist p11, p11 BID, BID
简单描述：Goat Polyclonal Anti-Human BID (C-Terminal) Antibody . Validated for use in WB, E.
生物商城：http://www.annoron.com
办公电话：010-56256916
官方售后：400-965-8633
企业 QQ：3212874516、3198592576
地 址：北京大兴经济技术开发区(亦庄)同济中路7号兴盛国际A栋4层
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验.: AR3A, human anti‐HCV E2 antibody (Law et al., ) E910, mouse anti‐HCV NS5A antibody (Lindenbach et al
antibody at 5 µg/ml for 45 min at 4 °C. Mouse anti-human NFB p65 monoclonal antibody sc-8008 (Santa Cruz, CA, USA) recognizes epitopes mapping the C amino-acid terminus of human origin NFB p65. After two washes in PBS–FCS, nuclei were incubated for 45 min
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
